Concall AI

Gufic Biosciences Limited — Q4 FY25 earnings call

Call held 2 Jun 2025

Management summary

Gufic Biosciences reported a challenging Q4 FY25 with significant declines in EBITDA and PAT, primarily attributed to the absorption of fixed costs (interest, depreciation, salaries) from the newly capitalized Indore plant. While full-year revenue saw marginal growth, profitability was impacted by these new costs and price erosion in key molecules. Management outlined strategies for Indore's ramp-up, aiming for EBITDA breakeven in FY26 and net profit breakeven in FY27, alongside expansion plans for its Botulinum Toxin and fertility segments.

Highlights

Q4 FY25 Revenue from operations was ₹205 crores, up 5.1% YoY from ₹195 crores in Q4 FY24.
Q4 FY25 EBITDA stood at ₹27 crores, a 23.1% decline YoY from ₹35.1 crores in Q4 FY24.
Q4 FY25 EBITDA margin was 13.17%, down from 18% in Q4 FY24, primarily due to Indore plant's fixed costs.
Q4 FY25 PAT was ₹8 crores, a 60% decline YoY from ₹20 crores in Q4 FY24, with PAT margin at 3.90%.
Full-year FY25 Revenue from operations was ₹819.8 crores, a modest 1.6% increase YoY from ₹806.7 crores in FY24.
Full-year FY25 PAT was ₹69.9 crores, down 18.9% YoY from ₹86.2 crores in FY24, with PAT margin at 8.53%.
The Indore facility incurred ₹8 crores in incremental depreciation and interest in Q4 FY25, expected to reach ₹36 crores for full FY26.
Botulinum Toxin (Stunnox) has treated 50,000 patients since launch and aims for ₹100 crore revenue in the next 3 years.

Concerns

Increased fixed costs from Indore plant impacting profitability

Key financials

2 periods

Headline

Revenue (FY)
₹819.8 Cr
YoY +1.6%
EBITDA (FY)
₹138.6 Cr
YoY -6.3%
EBITDA Margin (FY)
16.9%
PAT (FY)
₹69.9 Cr
YoY -18.9%
PAT Margin (FY)
8.5%

Q4

Revenue
₹205 Cr
YoY +5.1%
EBITDA
₹27 Cr
YoY -23.1%
EBITDA Margin
13.2%
PAT
₹8 Cr
YoY -60%
PAT Margin
3.9%

What they filed

Q1 FY27: revenue up 15.0%, net profit up 83.3% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	204	208	205	227	230 +13%	231 +11%	252 +23%	261 +15%
Expenses	166	174	178	195	195	195	206	214
EBITDA	39	34	27	32	36 −8%	36 +6%	46 +70%	47 +47%
Margin	19%	16%	13%	14%	16%	16%	18%	18%
Other income	0	2	0	1	2	1	-1	0
Interest	5	5	8	9	10	8	9	9
Depreciation	4	5	8	8	8	8	8	8
Profit before tax	29	26	11	16	21 −28%	21 −19%	28 +155%	30 +88%
Tax rate	26%	26%	26%	26%	27%	26%	26%	26%
Net profit	22	19	8	12	15 −32%	16 −16%	21 +163%	22 +83%
EPS	2.17	1.93	0.79	1.20	1.49	1.55	2.05	2.24

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Domestic Revenue Contribution
52% Percentage of Total Revenue
International Revenue Contribution
16% Percentage of Total Revenue
CMO Business Contribution
25% Percentage of Total Revenue
API Business Contribution
7% Percentage of Total Revenue
Domestic Critical Care Revenue Contribution
50% Percentage of Domestic Revenue
Domestic Fertility/Gynec Revenue Contribution
25% Percentage of Domestic Revenue
Domestic Mass Marketing (Nutraceutical/Ayurvedic) Revenue Contribution
16% Percentage of Domestic Revenue
Domestic Neurological/Aesthetic (Toxin) Revenue Contribution
4% Percentage of Domestic Revenue

Guidance & targets

Profitability

Indore Plant EBITDA Breakeven Profitability · FY26 · High confidence Breakeven

We expect EBITDA breakeven from Indore in FY '26 when incremental interest and depreciation will total around 36 crores for the full year.

— Avik Das
Indore Plant Net Profit Breakeven Profitability · FY27 · Medium confidence Breakeven

And what you rightly said in terms of even managing the interest and the depreciation, we should be breaking even next year. That's how we would say it.

— Pranav Choksi

Capacity

Indore Plant Capacity Utilization for EBITDA Breakeven Capacity · FY26 · High confidence 30%

So, when we say 30% is when we are committing on even the interest and, what do you call, the depreciation also to be taken care of on a monthly basis. That would happen next year only. This year only the EBITDA, we would be breakeven and a little bit positive.

— Pranav Choksi
Indore Plant Peak Capacity Utilization Capacity · FY28 · Medium confidence 70-75%

I think '28 is a better bet because we have a lot of, I would say, registrations and processes. International market, what we are mostly trying to cater from Indore would be the regulated market. And that is why we hope that '28 should be a good time where we can see at least majority reaching to at least close to 70%-75%, yes, or more.

— Pranav Choksi

Revenue

Indore Plant Peak Revenue Revenue · next 4-5 years (by FY28-29) · Medium confidence ₹800-900 crores

But like I said, we foresee the max revenue from, I will not say max. The most optimum max revenue should be around 800, which we hope that in the next four to five years we can achieve

— Pranav Choksi
Indore Plant Revenue Contribution Revenue · FY26 · High confidence ₹100-150 crores

So, we hope that anything around Rs. 100 to 150 crores bare minimum we need to extract from Indore this year.

— Pranav Choksi
Botulinum Toxin Revenue Revenue · next 3 years · Medium confidence ₹100 crore

But I still feel we hope that we can reach a Rs. 100 crore figure in terms of revenue in the next 3 years max for toxin as a whole.

— Pranav Choksi
Eclin Brand Revenue Revenue · going forward · Medium confidence ₹20-22 crore

But since we have taken the early mover advantage, we feel as a size for us, we are hoping that we can create at least a Rs. 20-22 crore brand from this going forward for Eclin.

— Pranav Choksi
IVIG in NeuroCare Revenue Revenue · going forward · Medium confidence ₹10 crore

So, it's a product basket expansion keeping in mind to take care of overheads and that also we feel the numbers should at least help us for that Rs. 10 crore mark going forward in that NeuroCare division.

— Pranav Choksi
Contrast-Media (Iodine products) Minimum Revenue Revenue · future · Medium confidence ₹15-20 crores

So, anything around Rs. 15-20 crores is something we minimum feel for the iodine products.

— Pranav Choksi
Guficin Alpha Revenue Contribution Revenue · this year (FY26) · Medium confidence ₹8-9 crores

However, at least we can reach to a close to Rs. 8 crore to Rs. 9 crore mark in this year would be great for Guficin Alpha as such.

— Pranav Choksi

Market Share

Botulinum Toxin Aesthetics Market Share Market Share · this year (FY26) · Medium confidence 20-22%

Now with Vijay Bhai coming in from Galderma and along with Dr. Jyoti Jha and other team members, we want to first reach 20% to 22% market share this year in aesthetics.

— Pranav Choksi
Botulinum Toxin Neurology Market Penetration Market Share · this year (FY26) · Medium confidence 25-26%

And in neurology or therapeutic indication, we hope to come to at least 25% to 26% market penetration.

— Pranav Choksi

Revenue Share

International Business Revenue Share Revenue Share · next 2-3 years · Medium confidence 25%

From 16-18% today

International business is something which we feel should gradually move from that 16%-18% revenue share to close to 25% revenue share in the next 2 to 3 years.

— Pranav Choksi

Revenue Contribution

Contrast-Media Contribution to Critical Care Segment Revenue Contribution · next 2-3 years · Medium confidence 5-6%

Based on the import data and what we could see, we hope that as a contrast-media basket should at least remain of become a 5% to 6% contributor in the entire critical care segment thing down the line in next two to three years. So, that is what it is.

— Pranav Choksi

Capex

Indore Plant Incremental Depreciation and Interest Capex · FY26 · High confidence ₹36 crores

We expect EBITDA breakeven from Indore in FY '26 when incremental interest and depreciation will total around 36 crores for the full year.

— Avik Das

Risks & concerns

Increased fixed costs from Indore plant impacting profitability
high

Indore plant capitalized in Q3 FY25, leading to higher fixed costs (salaries, utilities, depreciation, interest) of ~₹8 crores in Q4 FY25, expected to be ₹36 crores for FY26, causing margin pressure for next 2-3 quarters.

Management acknowledged
Price erosion in key molecules
medium

Around 10-12 molecules (e.g., Meropenem, HCG, Enoxaparin, Cavim) saw significant API price erosion (0-50%), impacting rupee value margins, though percentage margins remained intact. Management believes this has bottomed out.

Management acknowledged
Long regulatory approval timelines for international markets
medium

Regulatory maturity and product registrations for regulated markets (US, EU) take 18-24 months, sometimes up to 30 months for other countries, delaying commercial revenue from Indore internationally.

Management acknowledged
Capacity constraints at Navsari plant
low

Navsari plant is 'chock-a-blocked' for lyophilized injectables, limiting growth from existing products and necessitating new product transfers to Indore.

Management acknowledged

Q&A highlights

3 direct

Botulinum Toxin (Stunnox) revenue, profit, market size, and future growth Direct

We have already reached 9% market share in terms of aesthetics and in neurology or therapeutic indication, we have reached approximately 15% to 16% market share. So, that normally contributes to approximately, I would say, a little bit less than around 3% of our revenue today. 3% to 4% of our revenue of Gufic is here... But I still feel we hope that we can reach a Rs. 100 crore figure in terms of revenue in the next 3 years max for toxin as a whole.

Reveals the current scale and ambitious growth targets for a high-margin, specialty product, highlighting its contribution to overall revenue and future potential.

Asked by Vishal Mehta, Oakland Capital

Indore facility's revenue potential, breakeven timeline, and impact on margins Direct

So, if you see, the gross margin has been increased, but because of the fixed cost, the profit has been come down. And this pressure will be continued for next two, three quarters, looking to the capacity utilization of the Indore plant because fixed costs, cost of interest and depreciation, that is accounting to be around Rs. 36 crore as a whole year. So, every quarter we have to incur around Rs. 9 crore. That will be going to have pressure on the margin... We hope that anything around Rs. 100 to 150 crores bare minimum we need to extract from Indore this year.

Clarifies the immediate financial drag of the Indore plant, its breakeven targets, and the expected revenue contribution in the near term, which is crucial for understanding future profitability.

Asked by Shrey Gandhi, Kothari Stock Broking; Srikant Parak, Prudent Investment; Rahul Girish Shah, Glostar LLP

Updates on fertility segment products (Urofollitropin Alpha, Supergraf, Guficin Alpha) and market opportunity Direct

So, the Urofollitropin alpha is basically our recombinant FSH which we will be initiating the clinical trials for DCGI or the CDSCO first, and then we hope to get approvals next year... However, for Supergraf, of course, the trials have been initiated... we hope that these trials will happen side by side and we should have some results by the end of this year for Supergraf... Guficin Alpha is our third product, which is our immunomodulator for recurrent implantation failure... at least we can reach to a close to Rs. 8 crore to Rs. 9 crore mark in this year would be great for Guficin Alpha as such.

Provides specific timelines for clinical trials and approvals for new fertility products, along with revenue expectations for products already in the market, indicating future growth drivers in a key segment.

Asked by Yohansh Geswani, Mittal Analytics

3 min read 7 chapters

Detailed narrative

Q4 FY25 Performance and Full-Year Overview

Gufic Biosciences reported a Q4 FY25 revenue of ₹205 crores, a 5.1% increase year-on-year. However, profitability saw a significant decline, with EBITDA falling 23.1% to ₹27 crores and PAT dropping 60% to ₹8 crores. The EBITDA margin contracted to 13.17% from 18% in Q4 FY24. For the full fiscal year FY25, revenue grew marginally by 1.6% to ₹819.8 crores, while PAT decreased by 18.9% to ₹69.9 crores, with the PAT margin at 8.53%.

Indore Facility: Costs, Ramp-up, and Future Potential

The newly capitalized Indore plant significantly impacted Q4 FY25 profitability, absorbing ₹8 crores in incremental fixed costs (interest, depreciation, salaries). Management expects these costs to total ₹36 crores for FY26. The plant aims for EBITDA breakeven in FY26 at approximately 30% capacity utilization, with net profit breakeven targeted for FY27. For FY26, Indore is projected to contribute a minimum of ₹100-150 crores in revenue, primarily from domestic markets. The facility's peak revenue potential is estimated at ₹800-900 crores, reaching 70-75% capacity utilization by FY28-29, contingent on international regulatory approvals.

Botulinum Toxin Business Expansion (Aesthaderm & NeuroCare)

Gufic's Botulinum Toxin Type A, Stunnox, has treated 50,000 patients since its launch. The company aims to achieve a 20-22% market share in aesthetics and 25-26% market penetration in neurology this year. The Botulinum Toxin business currently contributes 3-4% of Gufic's total revenue, with gross margins of 80-85%. Management targets ₹100 crore in revenue from this segment within the next three years, driven by increased awareness and expanded therapeutic indications.

Fertility Segment Developments

The fertility cluster is a key growth area, contributing approximately 25% to domestic revenue. Gufic is initiating clinical trials for Urofollitropin Alpha (recombinant FSH) with approvals expected next year. Trials for Supergraf (India's purest HMG) are underway, with results anticipated by the end of this year. The company also expects Guficin Alpha, an immunomodulator for recurrent implantation failure, to contribute ₹8-9 crores in revenue this year, as it works to establish its market presence.

International Business Growth Strategy

Gufic is aggressively expanding its international footprint, aiming to increase its revenue share from the current 16-18% to 25% in the next 2-3 years. Key initiatives include appointing a President of International Business, signing a distribution agreement covering 17 LATAM countries, and securing seven product approvals in Myanmar, Sri Lanka, and Cambodia. The company is also setting up rep offices in Vietnam and evaluating a presence in the Philippines, with a focus on regulated markets for Indore's output, expecting commercial revenue from these markets by late FY26 or early FY27.

Critical Care and Sparsh Cluster Initiatives

The critical care cluster, which accounts for over 50% of domestic revenue, is optimizing its sales teams to focus on high-potential hospitals. Cavim leads the Ceftazidime+Avibactam segment in 195 centers, and Gufic holds top positions in antifungals like Caspofungin and Micafungin. The Sparsh cluster is launching contrast-media offerings, with a soft launch already providing positive feedback. This product line is expected to become a 5-6% contributor to the critical care segment in the next 2-3 years, with iodine-based products alone projected to generate ₹15-20 crores in revenue.

Margin Pressure and Price Erosion

While gross margins have increased, overall profitability was pressured by higher fixed costs from the Indore plant and significant price erosion in 10-12 key molecules, including Meropenem, Human Chorionic Gonadotropin, Enoxaparin, and Cavim. The selling rate for Cavim, for instance, dropped from ₹1,200 to ₹680-700. Management believes this price erosion has bottomed out since September-December 2024, and expects revenue growth in FY26 to be driven by increased volumes and contributions from the Indore plant.

This is an AI-generated summary of a publicly available earnings call transcript.

View original transcript